Pregabalin Capsule
Product Images NDC 60760-507

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-507). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregab (Pregabalin 60760 507 60)

Pregabalin Capsules 150 mg label showing dosage form as capsules with a quantity of 60 per bottle. The label includes the NDC 60760-507-60, manufactured by SciGen Pharmaceuticals, Inc., Hauppauge, NY, and packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. Additional details include placeholders for lot number, expiration date, and Rx number, with instructions to use as directed and store at controlled room temperature 15°-30°C (59°-86°F).*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line chart depicting the percent of patients improved plotted against percent improvement in pain from baseline. It compares four categories: Pregabalin 200 mg three times a day, 100 mg three times a day, 25 mg three times a day, and a placebo group. The chart shows that higher doses of Pregabalin correlate with higher percentages of patient improvement.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day (dashed line) to placebo (dotted line), illustrating patient response distribution across different levels of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice daily, compared to placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percent of patients improved.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and Placebo, illustrating their relative effectiveness in pain improvement over a range of percentages.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting the percent of patients improved on the y-axis against the percent improvement in pain from baseline on the x-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing patient improvement curves across varying pain reduction percentages.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph showing responder rates (%) for two studies, E1 and E3, comparing placebo and different doses of pregabalin. In Study E1, doses range from 50mg/day to 600mg/day with BID dosing; in Study E3, doses include 300mg/day (BID) and 600mg/day (TID). The graph highlights statistically significant improvements versus placebo at various doses.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction as median percentage change from baseline versus dose in mg/day. The graph includes data points for four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID, with doses ranging from 0 to 600 mg/day and significant p-values indicated at various points.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline. It compares results for Pregabalin at 800 mg, 450 mg, and 300 mg daily doses against a placebo, with the Pregabalin 800 mg dose showing a higher percent of patients improved across increasing pain improvement percentages.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR (likely a clinical endpoint) over a period of 180 days for Pregabalin versus Placebo. The vertical axis shows the estimated percentage without LTR from 0% to 100%, and the horizontal axis represents the number of days. The solid line represents Pregabalin, showing a higher percentage of subjects without LTR over time compared to the dashed line representing Placebo, which declines more steeply and plateaus lower.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph showing the percent of subjects improved over a range of percent improvement from baseline to Week 12 BOCF. The graph compares Pregabalin, with a solid line, to a placebo, with a dashed line, across various improvement percentages on the x-axis and the corresponding percent of subjects improved on the y-axis.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved over varying percentages of improvement from baseline to week 16, based on the BOCF method. Two lines represent Pregabalin and Placebo groups, showing higher improvement percentages for Pregabalin across the range. The Y-axis shows percent of subjects improved, and the X-axis shows percent improved from baseline.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula panel showing the calculation method for creatinine clearance (CLcr), expressed as (140 minus age in years) multiplied by weight in kilograms divided by 72 times serum creatinine in mg/dL, with an adjustment factor of 0.85 for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin, an active ingredient in Pregabalin capsules 150 mg by St. Mary's Medical Park Pharmacy. The diagram shows the molecular configuration including carboxyl and amine groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.